Cancer Research Cell Death Mechanisms and Cancer Therapy  Genetics and Biology of Brain Cancer
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

Published online first on May 12, 2009
[Cancer Research, 10.1158/0008-5472.CAN-08-3441]
This Article
Right arrow Full Text (Online First [PDF])
Right arrow Supplementary Data
Right arrow All Versions of this Article:
0008-5472.CAN-08-3441v1
69/10/4116    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hennessy, B. T.
Right arrow Articles by Mills, G. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hennessy, B. T.
Right arrow Articles by Mills, G. B.

Cell, Tumor, and Stem Cell Biology

Characterization of a Naturally Occurring Breast Cancer Subset Enriched in Epithelial-to-Mesenchymal Transition and Stem Cell Characteristics

Bryan T. Hennessy 1, 2, 6*, Ana-Maria Gonzalez-Angulo 2, 3, 6, Katherine Stemke-Hale 2, 6, Michael Z. Gilcrease 4, Savitri Krishnamurthy 4, Ju-Seog Lee 2, Jane Fridlyand 7, Aysegul Sahin 4, Roshan Agarwal 2, Corwin Joy 5, Wenbin Liu 5, David Stivers 5, Keith Baggerly 5, Mark Carey 2, 6, Ana Lluch 8, Carlos Monteagudo 9, Xiaping He 10, Victor Weigman 10, Cheng Fan 10, Juan Palazzo 11, Gabriel N. Hortobagyi 3, Laura K. Nolden 2, Nicholas J. Wang 7, Vicente Valero 3, Joe W. Gray 7, Charles M. Perou 10, and Gordon B. Mills 2, 6

Departments of 1Gynecologic Medical Oncology, 2Systems Biology, 3Breast Medical Oncology, 4Pathology, and 5Bioinformatics and Computational Biology and 6Kleberg Center for Molecular Markers, The University of Texas M. D. Anderson Cancer Center, Houston, Texas; 7Lawrence Berkeley National Laboratory, Berkeley, California; 8Clinic Hospital and 9University of Valencia, Valencia, Spain; 10Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina; and 11Department of Pathology, Thomas Jefferson University, Philadelphia, Pennsylvania

* To whom correspondence should be addressed. E-mail: bhennessy{at}mdanderson.org.


   Abstract

Metaplastic breast cancers (MBC) are aggressive, chemoresistant tumors characterized by lineage plasticity. To advance understanding of their pathogenesis and relatedness to other breast cancer subtypes, 28 MBCs were compared with common breast cancers using comparative genomic hybridization, transcriptional profiling, and reverse-phase protein arrays and by sequencing for common breast cancer mutations. MBCs showed unique DNA copy number aberrations compared with common breast cancers. PIK3CA mutations were detected in 9 of 19 MBCs (47.4%) versus 80 of 232 hormone receptor–positive cancers (34.5%; P = 0.32), 17 of 75 HER-2–positive samples (22.7%; P = 0.04), 20 of 240 basal-like cancers (8.3%; P < 0.0001), and 0 of 14 claudin-low tumors (P = 0.004). Of 7 phosphatidylinositol 3-kinase/AKT pathway phosphorylation sites, 6 were more highly phosphorylated in MBCs than in other breast tumor subtypes. The majority of MBCs displayed mRNA profiles different from those of the most common, including basal-like cancers. By transcriptional profiling, MBCs and the recently identified claudin-low breast cancer subset constitute related receptor-negative subgroups characterized by low expression of GATA3-regulated genes and of genes responsible for cell-cell adhesion with enrichment for markers linked to stem cell function and epithelial-to-mesenchymal transition (EMT). In contrast to other breast cancers, claudin-low tumors and most MBCs showed a significant similarity to a "tumorigenic" signature defined using CD44+/CD24- breast tumor–initiating stem cell–like cells. MBCs and claudin-low tumors are thus enriched in EMT and stem cell–like features, and may arise from an earlier, more chemoresistant breast epithelial precursor than basal-like or luminal cancers. PIK3CA mutations, EMT, and stem cell-like characteristics likely contribute to the poor outcomes of MBC and suggest novel therapeutic targets. [Cancer Res 2009;69(10):4116–24]

Key Words: Breast, Cancer, Metaplastic




This article has been cited by other articles:


Home page
Genes Dev.Home page
J. E. Visvader
Keeping abreast of the mammary epithelial hierarchy and breast tumorigenesis
Genes & Dev., November 15, 2009; 23(22): 2563 - 2577.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
C. J. Creighton, X. Li, M. Landis, J. M. Dixon, V. M. Neumeister, A. Sjolund, D. L. Rimm, H. Wong, A. Rodriguez, J. I. Herschkowitz, et al.
Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features
PNAS, August 18, 2009; 106(33): 13820 - 13825.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2009 by the American Association for Cancer Research.